François Guilhot

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Stephen G. O’Brien, François Guilhot, Richard A. Larson et al. · New England Journal of Medicine · 2003 · 3.5K citations · Full text

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

Hagop Kantarjian, Charles L. Sawyers, Andreas Hochhaus et al. · New England Journal of Medicine · 2002 · 2K citations · Full text

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot et al. · The Lancet Oncology · 2010 · 1.5K citations

Hematological Malignancy, Oncology, Chronic Myeloid Leukaemia +8

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Andreas Hochhaus, Richard A. Larson, François Guilhot et al. · New England Journal of Medicine · 2017 · 1.2K citations · Full text